MEDIPOSTCO.,LTD.
Medipost, founded in 2000 and KOSDAQ-listed in 2005, specializes in cord blood banking and stem cell therapeutics.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2000 and listed on KOSDAQ in 2005, Medipost specializes in cord blood banking and stem cell therapeutics. It operates the cord blood bank brand Celltree, the knee osteoarthritis stem cell therapy Cartistem, and the health functional food brand Mobita, and is developing Neumostem, a treatment for bronchopulmonary dysplasia in premature infants. Consolidated revenue rose 2.9% year over year to KRW 70.7 billion; Cartistem received FDA IND approval for a US Phase 3 trial, and Medipost signed an agreement transferring exclusive Japan distribution rights to MEDIPOST K.K. for milestone payments of USD 4.5 million plus running royalties.
Regulatory approvals
data.go.kr1 Orphan Drug designations · 2014 / 1 Korean MFDS drug approvals · 2021
- Orphan동종 제대혈유래 중간엽줄기세포2014-07-24Orphan Drug designation · in development20140118408
- MFDS drugCARTISTEM(human Umbilical Cord Blood-derived Mesenchymal Stem Cells)2021-08-19Drug · Prescription · Approval202106062
Clinical trials
data.go.kr11 MFDS clinical trial authorisations · 2012–2021 (Phase 2 5 · Phase 1 2 · Phase 1/2a 2 · Phase 1/2 1 · Phase 3 1)
- Phase 2SMUP-IA-012021-10-26
6 trial sites
- Phase 1SMUP-IA-012019-06-25
1 trial site
- Phase 1SMUP-IA-012019-05-31
1 trial site
- Phase 2뉴모스템(PNEUMOSTEM)2019-03-29
2 trial sites
- Phase 2뉴모스템(PNEUMOSTEM)2017-12-19
2 trial sites
- Phase 1/2a뉴로스템2016-09-13
1 trial site
- Phase 2뉴모스템(PNEUMOSTEM)2015-11-12
2 trial sites
- Phase 1/2카티스템 (동종 제대혈유래 중간엽줄기세포)2014-06-09
1 trial site
- Phase 1/2a뉴로스템2013-09-10
1 trial site
- Phase 2뉴모스템(PNEUMOSTEM)2012-09-25
2 trial sites
- Phase 3카티스템2012-05-16
10 trial sites
Companies in the same categoryPharma & CDMO
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Founded and listed on KOSDAQ in 2015, Kolmar BioTech is a nonclinical CRO providing efficacy testing for anticancer and metabolic disease drug candidates.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition